Glusod

Glusod is a prescription medication that contains the active ingredient empagliflozin, an SGLT2 inhibitor administered orally for the treatment of type 2 diabetes mellitus. Marketed in the European Union, Glusod reduces renal glucose reabsorption, increasing urinary glucose excretion. The tablet’s dosage strength is determined by the prescribing physician, and it is intended for patients following medical guidance and should be used as part of a comprehensive diabetes management plan.

Glusod is indicated for the management of hyperglycemia in adults with type 2 diabetes mellitus, typically as an adjunct to diet and exercise.

- As monotherapy when metformin is not tolerated. - In combination with metformin to improve glycemic control. - Added to insulin therapy to reduce insulin dose requirements. - Used in patients with established cardiovascular risk to provide renal and cardiovascular benefits. - May be considered when additional oral agents are needed to achieve target HbA1c.

The safety profile of Glusod reflects the pharmacology of empagliflozin and includes both frequent, mild events and less common, serious reactions.

Common: - Increased urinary frequency. - Genital mycotic infections such as candidiasis. - Thirst or dry mouth. - Mild hypotension, especially in the elderly or those on diuretics.

Serious: - Euglycemic diabetic ketoacidosis. - Acute kidney injury. - Severe dehydration. - Fournier's gangrene (necrotizing fasciitis of the perineum).

Before initiating Glusod, healthcare providers should evaluate several clinical factors to minimize risk.

- Assess renal function; avoid use in severe renal impairment. - Monitor for signs of hypotension, particularly in patients on antihypertensives. - Evaluate risk of genital infections; counsel on hygiene. - Review history of ketoacidosis; discontinue if metabolic acidosis occurs. - Ensure adequate hydration to reduce dehydration risk. - Use caution in elderly patients due to orthostatic effects.

Glusod may interact with other medicines, influencing its efficacy or safety.

Avoid: - Concomitant use with other SGLT2 inhibitors (duplicate therapy). - Strong diuretics that may exacerbate dehydration. - Medications that cause significant hypoglycemia (e.g., insulin, sulfonylureas) without dose adjustment.

Use with caution: - Loop diuretics – monitor volume status. - ACE inhibitors or ARBs – watch renal function and potassium levels. - Antihypertensive agents – observe blood pressure. - Rifampin – may reduce empagliflozin plasma concentrations.